Antriabio Inc (ANTB) 0.5800 $ANTB
AntriaBio, Inc. to Present at 26th Annual ROTH Conference
Marketwire - Thu Mar 06, 7:05AM CST
AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical company focused on developing novel therapeutics for the diabetes market, announced today that Nevan Elam, Chairman and Chief Executive Officer is scheduled to present at the 26th Annual ROTH Conference. The conference is taking place March 9-12, 2014, at The Ritz-Carlton, Laguna Niguel, in Dana Point, CA.
AntriaBio to Present at 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014
Marketwire - Wed Feb 05, 7:05AM CST
AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical company focused on developing novel therapeutics for the diabetes market, announced today that the Company will be presenting at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 2:30 p.m. Eastern Time. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual BIO CEO & Investor Conference will take place February 10-11 at the Waldorf Astoria in New York City.
AntriaBio Inc concludes bridge financing to advance AB101 into clinical development for the treatment of diabetes
M2 - Fri Jan 17, 4:46AM CST
Biopharmaceutical company AntriaBio Inc (OTCQB:ANTB) reported on Thursday that it has completed a USD2.7m bridge note financing in an exempt private placement transaction with a number of accredited investors, with Paulson Investment Company Inc as the sole placement agent.
AntriaBio Announces Closing of Bridge Financing
Marketwire - Thu Jan 16, 9:07AM CST
AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical company focused on developing novel therapeutics for the diabetes market, announced today that it has closed a $2.7 million bridge note financing (the "Bridge Financing") in an exempt private placement transaction with a number of accredited investors. Paulson Investment Company, Inc. served as the Company's sole placement agent in the transaction.
AntriaBio Granted European Patent Allowance for Method of Preparing Site-Specific Protein Conjugates
Marketwire - Wed Jul 24, 7:30AM CDT
AntriaBio, Inc. (OTCQB: ANTB) announced today that it has received an allowance from the European Patent Office for Patent Application No. 04759347.0 entitled "Method for Preparation of Site-Specific Protein Conjugates" with claims directed to the Company's lead diabetes product candidate, AB101. This patent was also allowed in Australia.
AntriaBio Initiates Effort to Raise up to $12 Million in a Private Placement
Marketwire - Mon Jul 01, 7:31AM CDT
AntriaBio, Inc. (OTCQB: ANTB), a clinical-stage biopharmaceutical company developing therapies for the treatment of diabetes, announced today that as a result of expressions of interest from potential investors, it intends to raise up to $12 million as part of a private placement of common stock.
AntriaBio Set for a Major Short Squeeze
Marketwire - Thu Mar 14, 10:50AM CDT
A handful of early investors are fighting an uphill battle after investing in shares of AntriaBio (OTCBB: ANTB), which recently swooped in to snag an intriguing lead diabetes product, AB101, after a private firm had already invested more than $100 million into the formulation, manufacturing and intellectual property development of the injectable once-a-week basal insulin solution for diabetics who are otherwise forced to take shots on a daily basis.
Once-a-Week Insulin Shot Could Help Growing Diabetes Patient Base and Spell Huge Profits for Investors
Marketwire - Fri Feb 22, 6:23AM CST
In January 2013, newly trading AntriaBio, Inc. (OTCQB: ANTB) acquired one of the most-interesting and buzzworthy assets we've seen in some time from a private company called PR Pharmaceuticals.
AntriaBio Appoints Two Industry Leaders to Its Management Team
Marketwire - Tue Feb 19, 9:38AM CST
AntriaBio, Inc. (OTCQB: ANTB) is pleased to announce the appointment, on January 31, 2013, of two new members to its management team: Nevan Elam, as AntriaBio's President and Chief Executive Officer and Sankaram Mantripragada, Ph.D., as AntriaBio's Chief Scientific Officer.
AntriaBio Announces Stock Ticker Symbol Change to ANTB
Marketwire - Fri Feb 08, 9:45AM CST
AntriaBio, Inc. ("AntriaBio") today announced that FINRA has approved a change of the Company's stock ticker symbol. Effective today, the Company's common shares will commence trading on the OTC Bulletin Board under the trading symbol "ANTB" (OTCQB: ANTB). The previous trading symbol was "FMYY" (OTCQB: FMYY).
AntriaBio, Inc. to Present at 26th Annual ROTH Conference
Marketwire - Thu Mar 06, 7:05AM CST
AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical company focused on developing novel therapeutics for the diabetes market, announced today that Nevan Elam, Chairman and Chief Executive Officer is scheduled to present at the 26th Annual ROTH Conference. The conference is taking place March 9-12, 2014, at The Ritz-Carlton, Laguna Niguel, in Dana Point, CA.
AntriaBio to Present at 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014
Marketwire - Wed Feb 05, 7:05AM CST
AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical company focused on developing novel therapeutics for the diabetes market, announced today that the Company will be presenting at the 16th Annual BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 2:30 p.m. Eastern Time. Hosted by the Biotechnology Industry Organization (BIO), the 16th Annual BIO CEO & Investor Conference will take place February 10-11 at the Waldorf Astoria in New York City.
AntriaBio Inc concludes bridge financing to advance AB101 into clinical development for the treatment of diabetes
M2 - Fri Jan 17, 4:46AM CST
Biopharmaceutical company AntriaBio Inc (OTCQB:ANTB) reported on Thursday that it has completed a USD2.7m bridge note financing in an exempt private placement transaction with a number of accredited investors, with Paulson Investment Company Inc as the sole placement agent.
AntriaBio Announces Closing of Bridge Financing
Marketwire - Thu Jan 16, 9:07AM CST
AntriaBio, Inc. (OTCQB: ANTB), a biopharmaceutical company focused on developing novel therapeutics for the diabetes market, announced today that it has closed a $2.7 million bridge note financing (the "Bridge Financing") in an exempt private placement transaction with a number of accredited investors. Paulson Investment Company, Inc. served as the Company's sole placement agent in the transaction.
AntriaBio Granted European Patent Allowance for Method of Preparing Site-Specific Protein Conjugates
Marketwire - Wed Jul 24, 7:30AM CDT
AntriaBio, Inc. (OTCQB: ANTB) announced today that it has received an allowance from the European Patent Office for Patent Application No. 04759347.0 entitled "Method for Preparation of Site-Specific Protein Conjugates" with claims directed to the Company's lead diabetes product candidate, AB101. This patent was also allowed in Australia.
AntriaBio Initiates Effort to Raise up to $12 Million in a Private Placement
Marketwire - Mon Jul 01, 7:31AM CDT
AntriaBio, Inc. (OTCQB: ANTB), a clinical-stage biopharmaceutical company developing therapies for the treatment of diabetes, announced today that as a result of expressions of interest from potential investors, it intends to raise up to $12 million as part of a private placement of common stock.
AntriaBio Set for a Major Short Squeeze
Marketwire - Thu Mar 14, 10:50AM CDT
A handful of early investors are fighting an uphill battle after investing in shares of AntriaBio (OTCBB: ANTB), which recently swooped in to snag an intriguing lead diabetes product, AB101, after a private firm had already invested more than $100 million into the formulation, manufacturing and intellectual property development of the injectable once-a-week basal insulin solution for diabetics who are otherwise forced to take shots on a daily basis.
Once-a-Week Insulin Shot Could Help Growing Diabetes Patient Base and Spell Huge Profits for Investors
Marketwire - Fri Feb 22, 6:23AM CST
In January 2013, newly trading AntriaBio, Inc. (OTCQB: ANTB) acquired one of the most-interesting and buzzworthy assets we've seen in some time from a private company called PR Pharmaceuticals.
AntriaBio Appoints Two Industry Leaders to Its Management Team
Marketwire - Tue Feb 19, 9:38AM CST
AntriaBio, Inc. (OTCQB: ANTB) is pleased to announce the appointment, on January 31, 2013, of two new members to its management team: Nevan Elam, as AntriaBio's President and Chief Executive Officer and Sankaram Mantripragada, Ph.D., as AntriaBio's Chief Scientific Officer.
AntriaBio Announces Stock Ticker Symbol Change to ANTB
Marketwire - Fri Feb 08, 9:45AM CST
AntriaBio, Inc. ("AntriaBio") today announced that FINRA has approved a change of the Company's stock ticker symbol. Effective today, the Company's common shares will commence trading on the OTC Bulletin Board under the trading symbol "ANTB" (OTCQB: ANTB). The previous trading symbol was "FMYY" (OTCQB: FMYY).
